Please assess the completion status of the following clinical trial:

Trial Title: Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1~* Hemoglobin \>= 9 g/dL~* Absolute neutrophil count \>= 1500/mm\^3~* Platelet count \>= 100,000/mm\^3~* Creatinine =\< 1.5 upper limit of normal (ULN) AND creatinine clearance (CrCl) \> 50 mL/min by Cockcroft-Gault equation~* Males = (140 -age (yrs) (body weight (kg)/(72) (serum creatinine) (mg/dL)~* Females = 0.85 \* (140-age (yrs) (body weight (kg)/(72)(serum creatinine (mg/dL)~* Bilirubin \< ULN~* Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 1.5 ULN if without liver metastases~* AST/ALT =\< 2.5 x ULN if with liver metastases~* Coagulation parameters: international normalized ratio (INR) =\< 2, prothrombin time (PT) and partial thromboplastin time (PTT) \< 1.5 X institutional ULN~* Have measurable disease per RECIST 1.1 criteria~* Histologically or cytologically proven adenocarcinoma of the colon or rectum~* Prior progression following a fluoropyrimidine-based therapy and progression following or intolerance to irinotecan and oxaliplatin, as well as anti-epidermal growth factor receptor (EGFR) therapy (e.g., panitumumab or cetuximab) for rat sarcoma viral oncogene homolog (RAS) wild-type patients~* Ability to swallow and retain oral medication~* Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for three months following completion of therapy; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately~* Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure~Exclusion Criteria:~* Prior treatment with nintedanib~* Prior treatment with regorafenib~* Major injuries or surgery within the 4 weeks prior to initiation of therapy with incomplete wound healing or planned surgery during the on-study treatment period~* Uncontrolled hypertension: systolic blood pressure \>= 160, diastolic blood pressure \>= 90~* Urine protein/creatinine ratio \>= 1.0~* History of clinically significant hemorrhagic or thrombotic event within the past 6 months, not including uncomplicated catheter-associated venous thrombosis; patients on anti-coagulation are not permitted to be on any oral formulations (warfarin, rivaroxaban, dabigatran, etc.) due to concern for drug-drug interaction~* Unstable angina, symptomatic congestive heart failure or cardiac arrhythmia requiring anti-arrhythmic therapy (beta-blockers, calcium channel blockers and digoxin are allowed)~* History of cerebrovascular or myocardial ischemia within 6 months of initiation~* Known inherited predisposition to bleeding or thrombosis~* Known active or chronic hepatitis B or C or human immunodeficiency virus (HIV)~* Untreated brain metastases~* History of second primary malignancy diagnosed within 3 years prior to enrollment, excluding:~  * In-situ cervical carcinoma~ * Superficial bladder cancer~ * Non-melanoma skin cancer~ * Stage I breast cancer~ * Low grade (Gleason =\< 6) localized prostate cancer~ * Any additional malignancy which has been in clinical remission for at least 1 year~* Pregnant or nursing female participants~* Unwilling or unable to follow protocol requirements~* Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study drug~* Received an investigational agent within 4 weeks prior to enrollment~* PHASE I: History of intolerance to capecitabine at doses =\< 1000 mg/m\^2 BID, as defined by documented \>= grade 3 hand-foot syndrome, documented severe diarrhea requiring hospitalization, or other documented severe adverse events (AEs) attributable to capecitabine~* PHASE II: History of intolerance to capecitabine at doses below 1000 mg/m\^2 BID, as defined by documented \>= grade 3 hand-foot syndrome; documented severe diarrhea requiring hospitalization; or other documented severe AEs attributable to capecitabine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (capecitabine, nintedanib) (Type: EXPERIMENTAL): Patients received capecitabine PO BID (every 12 hours) on days 1-14 and nintedanib PO BID (every 12 hours) on days 1-21. Courses repeated every 21 days in the absence of disease progression or unacceptable toxicity.
- Treatment (capecitabine , nintendanib) (Type: EXPERIMENTAL): Patients receive the highest safe dose of the combination of nintedanib and capcitabine.

Based on this trial design, predict the completion outcome and termination type (if applicable).